Anticancer drugs in surface waters. What can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?

Environment International

Volumn 39, Issue 1, 2012, Pages 73-86

  Besse, Jean Philippe ^a   Latour, Jean François ^b   Garric, Jeanne ^a  

^a UR MALY   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Anticancer drugs; Antineoplastic; Ecotoxicity; Occurrence; Pharmaceuticals; Surface water

Indexed keywords

DRUG PRODUCTS; EFFLUENTS; ENZYMES; METABOLISM; METABOLITES; MOLECULES; MONOCLONAL ANTIBODIES; SURFACE WATERS; TOXICITY; WASTEWATER; WASTEWATER TREATMENT;

ACTIVE METABOLITES; ANTICANCER DRUG; ANTINEOPLASTIC; AQUATIC ENVIRONMENTS; CYTOSTATIC; CYTOTOXIC; ECOTOXICITY; ECOTOXICOLOGICAL EFFECTS; ECOTOXICOLOGICAL RISKS; ECOTOXICOLOGICAL STUDY; ENDOCRINE THERAPY; ENVIRONMENTAL SIGNIFICANCE; HOSPITAL EFFLUENT; IN-VITRO ASSAYS; ISOLATED MOLECULES; LOCAL SCALE; LONG-TERM EFFECTS; NON-TARGET ORGANISM; OCCURRENCE; PARENT MOLECULES; PROTEIN KINASE; RESEARCH NEEDS; TAMOXIFEN; THERAPEUTIC CLASS; WASTEWATER TREATMENT PLANTS;

DRUG THERAPY;

ALKYLATING AGENT; ANTIANDROGEN; ANTIESTROGEN; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; CYTOTOXIC ANTIBODY; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; ESTRAMUSTINE; FLUOROURACIL; FLUTAMIDE; GEMCITABINE; GONADORELIN DERIVATIVE; HYDROXYUREA; IFOSFAMIDE; IMATINIB; INTERCALATING AGENT; LAPATINIB; MITOTANE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; PROTEIN KINASE INHIBITOR; SURFACE WATER; TAMOXIFEN; UNINDEXED DRUG;

ACCURACY ASSESSMENT; AQUATIC ENVIRONMENT; BIOMONITORING; DRUG; ECOTOXICOLOGY; EFFLUENT; ENVIRONMENTAL FATE; METABOLITE; SURFACE WATER; TREND ANALYSIS; WASTEWATER; WATER TREATMENT;

AQUATIC ENVIRONMENT; ARTICLE; DRUG CYTOTOXICITY; ECOTOXICITY; EFFLUENT; ENVIRONMENTAL EXPOSURE; GENOTOXICITY; IN VITRO STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; WASTE WATER TREATMENT PLANT;

EID: 80355131689     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2011.10.002     Document Type: Article

References (89)

1. AFSSAPS. Agence Française de Sécurité Sanitaire des Produits de Santé. French consumption amounts for pharmaceuticals, including anticancer drugs (ATC class L01) for year 2004. 2006. Personal communication.
2. AFSSAPS. Agence Française de Sécurité Sanitaire des Produits de Santé. French consumption amounts for anticancer drugs (ATC class L01) for year 2008. 2009a. Personal communication.
3. AFSSAPS. Agence Française de Sécurité Sanitaire des Produits de Santé. French consumption amounts for endocrine therapy drugs (ATC class L02) for year 2008. 2009b. Personal communication.
4. Aherne G.W., Hardcastle A., Nield A.H. Cytotoxic drugs and the aquatic environment. Estimation of Bleomycin in river and water samples. J Pharm Pharmacol 1990, 42(10):741-742.
5. Aitken R.J., De Iuliis G.N. Origins and consequences of DNA damage in male germ cells. 2007. Reprod Biomed Online 2007, 14(6):727-733.
6. Andersen H.R., Wollenberger L., Halling-Sorensen B., Kusk K.E. Development of copepod nauplii to copepodites. A parameter for chronic toxicity including endocrine disruption. Environ Toxicol Chem 2001, 20(12):2821-2829.
7. Ashton D., Hilton M., Thomas K.V. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 2004, 333:167-184.
8. Backhaus T., Altenburger R., Boedeker W., Faust M., Scholze M., Grimme L.H. Predictability of the toxicity of a multiple mixture of dissimilarly acting chemicals to Vibrio fischeri. Environ Tox Chem 2000, 19(9):2348-2356.
9. Bantle J.A., Burton D.T., Dawson D.A., Dumont J.N., Finch R.A., Fort D.J., et al. Rayburn JR Fetax interlaboratory validation study: phase II testing. Environ Toxicol Chem 1994, 13(10):1629-1637.
10. BCB Banque Claude Bernard Last accessed august 2011. http://www.resip.fr.
11. Benyumov A., Gurvich V.J., Lis L.G., Williams B.W., Kirstein M.N. Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU. ChemMedChem 2011, 6(3):457-464.
12. Besse J.-P., Garric J. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation. Toxicol Lett 2008, 176(2):104-123.
13. Besse J.-P., Garric J. Progestagens for human use, exposure and hazard assessment for the aquatic environment. Environ Pollut 2009, 157(12):3485-3494.
14. Besse J.-P., Kausch-Barreto C., Garric J. Exposure assessment of pharmaceuticals and their metabolites in the aquatic environment: application to the French situation and preliminary prioritization. Hum Ecol Risk Assess 2008, 14(4):665-695.
15. Brian J.V., Harris C.A., Scholze M., Kortenkamp A., Booy P., Lamoree M., et al. Evidence of estrogenic mixture effects on the reproductive performance of fish. Environ Sci Technol 2007, 41(1):337-344.
16. Buerge I.J., Buser H.-R., Poiger T., Müller M.D. Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. Environ Sci Technol 2006, 40(23):7242-7250.
17. Catastini C., Mullot J.-U., Boukari S., Mazellier P., Levi Y., Cervantes P., et al. Assessment of antineoplastic drugs in effluents of two hospitals | [Identification de molécules anticancéreuses dans les effluents hospitaliers]. J Eur Hydrol 2008, 39(2):171-180.
18. Celiz M.D., Tso J., Aga D.S. Pharmaceutical metabolites in the environment: analytical challenges and ecological risks. Environ Toxicol Chem 2009, 28(12):2473-2484.
19. Cockshott I.D. Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet 2004, 43(13):855-878.
20. Coetsier C.M., Spinelli S., Lin L., Roig B., Touraud E. Discharge of pharmaceutical products (PPs) through a conventional biological sewage treatment plant: MECs vs PECs?. Environ Int 2009, 35(5):787-792.
21. De Young D.J., Bantle J.A., Hull M.A., Burks S.L. Differences in sensitivity to developmental toxicants as seen in Xenopus and Pimephales promelas embryos. Bull Environ Contam Toxicol 1996, 56(1):143-150.
22. EMEA Note for guidance on environmental risk assessment of medicinal products for human use. Doc. Ref. EMEA/CHMP/SWP/4447/00. Doc. Ref. EMEA/CHMP/SWP/4447/00 2006, European Agency for the Evaluation of Medicinal Products, London, UK.
23. Emmanuel E., Pierre M.G., Perrodin Y. Groundwater contamination by microbiological and chemical substances released from hospital wastewater: health risk assessment for drinking water consumers. Environ Int 2009, 35:718-726.
24. Ericson J.F. An evaluation of the OECD 308 water/sediment systems for investigating the biodegradation of pharmaceuticals. Environ Sci Technol 2007, 41:5803-5811.
25. Fabre G., Goldman I.D. Formation of 7-hydroxymethotrexate polyglutamyl derivatives and their cytotoxicity in human chronic myelogenous leukemia cells in vitro. Cancer Res 1985, 45:80-85.
26. FASS The Swedish medicines information engine. Läkemedelsfakta: Miljöinformation Last accessed march 2011. Available at. http://www.fass.se.
27. FDA-CDER Retrospective review of ecotoxicity data submitted in environmental assessments 1996, FDA Center for Drug Evaluation and Research, Rockville, MD, USA, (docket N 96N-0057).
28. Fent K., Weston A.A., Caminada D. Ecotoxicology of human pharmaceuticals. Aquat Toxicol 2006, 76(2):122-159.
29. Ferk F., Mišík M., Grummt T., Majer B., Fuerhacker M., Buchmann C., et al. Genotoxic effects of wastewater from an oncological ward. Mutat Res 2009, 672:69-75.
30. Frenzilli G., Nigro M., Lyons B.P. The Comet assay for the evaluation of genotoxic impact in aquatic environments. Mutat Res - RevMutat Res 2009, 681(1):80-92.
31. Gust M., Garric J., Giamberini L., Mons R., Abbaci K., Garnier F., et al. Sensitivity of New Zealand mudsnail Potamopyrgus antipodarum (Gray) to a specific aromatase inhibitor. Chemosphere 2010, 79(1):47-53.
32. Halling-Sørensen B., Nors Nielsen S., Lanzky P.F., Ingerslev F., Holten-Lützhøft H.C., Jørgensen S.E. Occurrence, fate and effects of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36(2):357-393.
33. Henschel K.P., Wenzel A., Diedrich M., Fliedner A. Environmental hazard assessment of pharmaceuticals. J Reg Toxicol Pharmacol. 1997, 25(3):220-225.
34. Hignite C., Aznaroff D.L. Drugs and drugs metabolites as environmental contaminants: chlorophenoxyisobutirate and salicylic acid in sewage effluent. Life Sci 1977, 20:337-341.
35. Jensen K.M., Kahl M.D., Makynen E.A., Korte J.J., Leino R.L., Butterworth B.C., et al. Characterization of responses to the antiandrogen flutamide in a short-term reproduction assay with the fathead minnow. Aquat Toxicol 2004, 70:99-110.
36. Johnson A.C., Jürgens M.D., Williams R.J., Kümmerer K., Kortenkamp A., Sumpter J.P. Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study. J Hydrol 2008, 348(1-2):167-175.
37. Jolibois B., Guerbet M. Evaluation of industrial, hospital and domestic wastewater genotoxicity with the Salmonella fluctuation test and the SOS chromotest. Mutat Res 2005, 565(2):151-162.
38. Joqueviel C., Martino L., Gilard V., Malet Martino M., Canal P., Niemeyer U. Urinary excretion of cyclophosphamide in humans determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab Dispos 1998, 26:418-428.
39. Kiffmeyer T., Götze H.-J., Jursch M., Lüders U. Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water. Fresenius J Anal Chem 1998, 361(2):185-191.
40. Kisanga E.R., Mellgren G., Lien E.A. Excretion of hydoxylated metabolites of Tamoxifen in human bile and urine. Anticancer Res 2005, 25:4487-4492.
41. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol 2002, 36:1202-1211.
42. Kümmerer K. Pharmaceuticals in the environment. Pharmaceuticals in the environment : sources, fate, effects and risks 2001, 1-8. Springer-Verlag, Berlin. K. Kümmerer (Ed.).
43. Kümmerer K., Al-Ahmad A. Biodegradability of the anti-tumour agents 5-fluorouracil, cytarabine and gemcitabine: impact of the chemical structure and synergistic toxicity with hospital effluent. Acta Hydroch Hydrob 1997, 25:166-172.
44. Kümmerer K., Steger-Hartmann T., Meyer M. Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage. Water Res 1997, 31(11):2705-2710.
45. Kümmerer K., Al-Ahmad A., Bertram B., Wießler M. Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry. Chemosphere 2000, 40(7):767-773.
46. Kümmerer K., Alexy R., Hüttig J., Schöll A. Standardized tests fail to assess the effects of antibiotics on environmental bacteria. Water Res 2004, 38(8):2111-2116.
47. Lacaze E., Geffard O., Bony S., Devaux A. Genotoxicity assessment in the amphipod Gammarus fossarum by use of the alkaline Comet assay. Mutat Res 2010, 700(1-2):32-38.
48. Lacaze E, Geffard O, Goyet D, Bony S, Devaux A. Linking genotoxic responses in Gammarus fossarum germ cells with reproduction impairment, using the Comet assay. Environ Res 2011;111(5):626-34.
49. Langford K., Thomas K.V. Input of selected human pharmaceutical metabolites into the Norwegian aquatic environment. J Environ Monit 2010, 13(2):416-421.
50. Lenz K., Hann S., Koellensperger G., Stefanka Z., Stingeder G., Weissenbacher N., et al. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge. Sci Totat Environ 2005, 345:141-152.
51. Lenz K., Mahnik S.N., Weissenbacher N., Mader R.M., Krenn P., Hann S., et al. Monitoring, removal and risk assessment of cytostatic drugs in hospital wastewater. Water Sci Technol 2007, 56:141-149.
52. Lingg R.M., Hempel G., Rots M.G., Van Zantwijk C.H., Boos J., Kaspers G.J.L. Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay. Cancer Chemother Pharmacol 2005, 56(3):322-327.
53. Liu X., Zhang J., Yin J., Duan H., Wu Y., Shao B. Analysis of hormone antagonists in clinical and municipal wastewater by isotopic dilution liquid chromatography tandem mass spectrometry. Anal Bioanal Chem 2010, 396(8):2977-2985.
54. Ludwig D.L., Pereira D.S., Zhu Z., Hicklin D.J., Bohlen P. Monoclonal antibody therapeutics and apoptosis. Oncogene 2003, 22:9097-9106.
55. Mahnik S.N., Rizovski B., Fuerhacker M., Mader R.M. Determination of 5-fluorouracil in hospital effluents. Anal Bioanal Chem 2004, 380(1):31-35.
56. Mahnik S.N., Lenz K., Weissenbacher N., Mader R.M., Fuerhacker M. Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system. Chemosphere 2007, 66(1):30-37.
57. Manning G., Plowman G.D., Hunter T., Sudarsanam S. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 2002, 27:514-520.
58. Micromedex Drugdex© Thomson micromedex©. Healthcare series Last accessed august 2011. http://http:www.micromedex.com/products/drugdex/.
59. Moldovan Z. Occurrences of pharmaceutical and personal care products as micropollutants in rivers from Romania. Chemosphere 2006, 64(11):1808-1817.
60. Mullot J-U. Modélisation des flux de médicaments dans les effluents hospitaliers. 2009. PhD thesis. University of Paris-Sud 11, France. Available at http://www.lspe.u-psud.fr/These%20Ju%20Mullot.pdf.
61. Mullot J.-U., Karolak S., Fontova A., Levi Y. Modeling of hospital wastewater pollution by pharmaceuticals: first results of Mediflux study carried out in three French hospitals. Water Sci Technol 2010, 62(12):2912-2919.
62. Panter G.H., Hutchinson T.H., Hurd K.S., Sherren A., Stanley R.D., Tyler C.R. Successful detection of (anti-)androgenic and aromatase inhibitors in pre-spawning adult fathead minnows (Pimephales promelas) using easily measured endpoints of sexual development. Aquat Toxicol 2004, 70(1):11-21.
63. Prado T., Silva D.M., Guilayn W.C., Rose T.L., Gaspar A.M.C., Miagostovich M.P. Quantification and molecular characterization of enteric viruses detected in effluents from two hospital wastewater treatment plants. Water Res 2011, 45(3):1287-1297.
64. Preston B.L., Snell T.W., Robertson T.L., Dingmann B.J. Use of freshwater rotifer Brachionus calyciflorus in screening assay for potential endocrine disruptors. Environ Toxicol Chem 2000, 19(12):2923-2928.
65. Reifferscheid G., Grummt T. Genotoxicity in German surface waters - results of a collaborative study. Water Air Soil Pollut 2000, 123(1-4):67-79.
66. Roberts P.H., Thomas K.W. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. Sci Totat Environ 2006, 356:143-153.
67. Rowney N.C., Johnson A.C., Williams R.J. Cytotoxic drugs in drinking water: a prediction and risk assessment exercise for the Thames catchment in the United Kingdom. Environ Toxicol Chem 2009, 28:2733-2743.
68. Runnalls T.J., Margiotta-Casaluci L., Kugathas S., Sumpter J.P. Pharmaceuticals in the aquatic environment: steroids and anti-steroids as high priorities for research. Hum Ecol Risk Assess 2010, 16:1318-1338.
69. Sárria M.P., Santos M.M., Reis-Henriques M.A., Vieira N.M., Monteiro N.M. The unpredictable effects of mixtures of androgenic and estrogenic chemicals on fish early life. Environ Int 2011, 37(2):418-424.
70. Sebire M., Allen Y., Bersuder P., Katsiadaki I. The model anti-androgen flutamide suppresses the expression of typical male stickleback reproductive behaviour. Aquat Toxicol 2008, 90(1):37-47.
71. Seither R.L., Rape T.J., Goldman I.D. Further studies on the pharmacologic effects of the 7-hydroxy catabolite of methotrexate in the L1210 murine leukemia cell. Biochem Pharmacol 1989, 38(5):815-822.
72. Steger-Hartmann T., Kümmerer K., Hartmann A. Trace analysis of the antineoplasics ifosfamide and cyclophosphamide in sewage water by two step solid phase extraction and gas-chromatography-mass spectrometry. J Chromatogr A 1996, 726(1-2):179.
73. Straub J.O. Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe. Integr Environ Assess Manag 2010, 6:540-566.
74. Sun L., Zha J., Spear P.A., Wang Z. Toxicity of the aromatase inhibitor letrozole to Japanese medaka (Oryzias latipes) eggs, larvae and breeding adults. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 2007, 145(4):533-541.
75. Sun L., Zha J., Wang Z. Effects of binary mixtures of estrogen and antiestrogens on Japanese medaka (Oryzias latipes). Aquat Toxicol 2009, 93(1):83-89.
76. Ternes T.A. Occurrence of drugs in German sewage treatment plants and rivers. Water Res 1998, 32:3245-3260.
77. Thomas K.V., Dye C., Schlabach M., Langford K.H. Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 2007, 9(12):1410-1418.
78. Trösken E.R., Scholz K., Lutz R.W., Volkel W., Zarn J.A., Lutz W.K. Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocrinol Res 2004, 30:387-394.
79. Trösken E.R., Fischer K., Völkel W., Lutz W.K. Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation. Toxicology 2006, 21933-21940.
80. Urbatzka R., Watermann B., Lutz I., Kloas W. Exposure of Xenopus laevis tadpoles to finasteride, an inhibitor of 5-α reductase activity, impairs spermatogenesis and alters hypophyseal feedback mechanisms. J Mol Endocrinol 2009, 43(5):209-219.
81. Veltkamp S.A., Pluim D., van Eijndhoven M.A.J., Bolijn M.J., Ong F.H.G., Govindarajan R., et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther 2008, 7(8):2415-2425.
82. Verlicchi P., Galletti A., Petrovic M., Barcelo D. Hospital effluents as a source of emerging pollutants: an overview of micropollutants and sustainable treatment options. J Hydrol 2010, 389(3-4):416-428.
83. Williams T.D., Caunter J.E., Lillicrap A.D., Hutchinson T.H., Gillings E.D., Duffell S. Evaluation of the reproductive effects of tamoxifen citrate in partial and full life-cycle studies using fathead minnows (Pimephales promelas). Environ Toxicol Chem 2007, 26(4):695-707.
84. Wu X., Hawse J.R., Subramaniam M., Goetz M.P., Ingle J.N., Spelsberg T.C. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res 2009, 69(5):1722-1727.
85. Yin J., Shao B., Zhang J., Li K. A preliminary study on the occurrence of cytostatic drugs in hospital effluents in Beijing, China. Bull Environ Contam Toxicol 2010, 84:39-45.
86. Zheng Y., Sun D., Sharma A.K., Chen G., Amin S., Lazarus P. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 2007, 35:1942-1948.
87. Zounkova R., Kovalova L., Blaha L., Dott W. Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites. Chemosphere 2010, 81(2):253-260.
88. Zounková R., Odráška P., Doležalová L., Hilscherová K., Maršálek B., Bláha L. Ecotoxicity and genotoxicity assessment of cytostatic pharmaceuticals. Environ Toxicol Chem 2007, 26(10):2208-2214.
89. Zuccato E., Castiglioni S., Fanelli R. Identification of the pharmaceuticals for human use contaminating the Italian aquatic environment. J Hazard Mater 2005, 122(3):205-209.